Open access
Sep 2026
17 Preclinical Study of Anti-CAIX/CD70 DFIR CAR-T Cell Therapy Secreting Anti-PD-1/CTLA-4 Bispecific Payload for Advanced Clear Cell Renal Cell Carcinoma Treatment
Anti-CAIX/CD70 DFIR CAR-T cell therapy simultaneously addresses three critical barriers to solid tumor immunotherapy — antigen heterogeneity, OTOT toxicity, and TME immunosuppression — and holds promise to achieve durable cures for advanced RCC.
Yu-Fei Wang
· The Oncologist · 0 citations